Any current/future new fundraising through debt or equity?

There is no immediate pressure on cash flow for the INR 5,000 crore polycarbonate resin manufacturing project, as Deepak Nitrite has a liquid surplus of around INR 800 crore. Payments to the technology partner Trinseo are being made in a phased manner. The company has available credit limits ("doable limits") to support funding if needed. Deepak Nitrite will communicate detailed funding plans through debt and equity after evaluating various options in due course. Overall, fundraising plans are balanced and contingent upon project engineering completion; no urgent or definitive debt/equity rais

Any current/future capex/capital investment/strategic investment?

INR 5,000 crore approved for manufacturing polycarbonate resins, including greenfield infrastructure and capital expenditure; commissioning expected around end FY27 and ramp-up by 2028-29. INR 2,000 crore capex for backward and forward integration projects (nitric acid, phenol, BPA) expected to start commissioning from H2 FY26. Total capex plan of approx. INR 14,000 crore till 2027; around INR 7,000 crore committed, balance for Phase 2 expansions. Investment in polycarbonate compounding via INR 34.5 crore in OXOC Chemical Limited for forward integration. New R&D center near Vadodara with appro

Future growth expectations in sales/revenue/volumes?

Anticipated demand uptick in legacy European customers in latter half of 2024 due to end of China's destocking, improving product pricing. Expecting margin expansion and volume recovery in Advanced Intermediates from Q4 FY25 onwards. Agrochemical segment sales impacted in earlier quarters but expected to recover strongly in H2 FY25 and CY25. Phenolics segment showing robust growth with revenues up 29% YoY in Q2 FY25, sustained by high utilization and favorable domestic consumption. Overall consolidated revenues grew 14% YoY in Q2 and 18% in H1 FY25, driven by phenolics and expanded cap

Future growth expectations in earnings/operating earnings/profits/EPS?

The company anticipates margin expansion starting Q4 FY25, driven by new product launches with margin-protection clauses via raw material cost pass-throughs. Phenolics segment shows strong growth with 29% revenue increase YoY and 15% EBIT margin, supporting profitability. Advanced Intermediates segment faces current pricing pressures but expects meaningful improvement from Q4 FY25 onwards. EBITDA for H1 FY25 grew 15% YoY to INR 647 crore with margins at 15%, indicating solid operational performance. Integrated new projects (BPA, phenol, polycarbonate) expected to enhance margins and resilience

IN US

Sale is live|00:00:00left today

Deepak Nitrite LtdQ3 FY24Chemicals & Petrochemicals

Deepak Nitrite Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,670P/E: 44.5Market Cap: ₹24.9K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Anticipated demand uptick in legacy European customers in latter half of 2024 due to end of China's destocking, improving product pricing.
→Expecting margin expansion and volume recovery in Advanced Intermediates from Q4 FY25 onwards.
→Agrochemical segment sales impacted in earlier quarters but expected to recover strongly in H2 FY25 and CY25.
→Phenolics segment showing robust growth with revenues up 29% YoY in Q2 FY25, sustained by high utilization and favorable domestic consumption.
→Overall consolidated revenues grew 14% YoY in Q2 and 18% in H1 FY25, driven by phenolics and expanded capacity.
→Expansion projects (e.g., nitric acid, polycarbonate, BPA, phenol) to commission from H2 FY25 through 2028, enabling volume growth and integrated business benefits.
→Focus on new products and markets, including strong R&D efforts, to broaden customer base and increase volumes.
→CY25 expected to be more positive with normalized global market conditions and stable growth trajectory.

Margin guidance

Category 3

→The company anticipates margin expansion starting Q4 FY25, driven by new product launches with margin-protection clauses via raw material cost pass-throughs.
→Phenolics segment shows strong growth with 29% revenue increase YoY and 15% EBIT margin, supporting profitability.
→Advanced Intermediates segment faces current pricing pressures but expects meaningful improvement from Q4 FY25 onwards.
→EBITDA for H1 FY25 grew 15% YoY to INR 647 crore with margins at 15%, indicating solid operational performance.
→Integrated new projects (BPA, phenol, polycarbonate) expected to enhance margins and resilience, with benefits ramping up from H2 FY26 onwards.
→INR 5,000 crore polycarbonate project (starting revenue flow from 2028) is part of a broader capex plan (~INR 14,000 crore) spread over next 3 years, aiming for long-term IRR and payback but detailed figures pending further project announcements.
→Company confident about recovery in agrochemical demand and normalization in CY25 supporting growth.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→There is no immediate pressure on cash flow for the INR 5,000 crore polycarbonate resin manufacturing project, as Deepak Nitrite has a liquid surplus of around INR 800 crore.
→Payments to the technology partner Trinseo are being made in a phased manner.
→The company has available credit limits ("doable limits") to support funding if needed.
→Deepak Nitrite will communicate detailed funding plans through debt and equity after evaluating various options in due course.
→Overall, fundraising plans are balanced and contingent upon project engineering completion; no urgent or definitive debt/equity raise has been announced so far.

Order book

The transcript provided from Deepak Nitrite Limited's Q2 & H1 FY25 earnings call does not explicitly mention the current or expected order book or pending orders. However, relevant points regarding demand and outlook include: - Anticipated demand uptick from legacy European customers in H2 FY25, aligning with end of China's destocking. - Recovery seen in various product segments with expected margin expansions from Q4 FY25 onwards. - Agrochemical segment faced volume revisions but expected significant improvement in volumes starting Q4 FY25. - Integration of backward and forward capacities (nitric acid, MIBK, MIBC, etc.) expected to enhance margins and ROCE starting H2 FY26. - Projects progressing well with commissioning expected in next 6-12 months to contribute to growth. No direct order book size or pending orders figures were disclosed.

Capex plans

Yes

→INR 5,000 crore approved for manufacturing polycarbonate resins, including greenfield infrastructure and capital expenditure; commissioning expected around end FY27 and ramp-up by 2028-29.
→INR 2,000 crore capex for backward and forward integration projects (nitric acid, phenol, BPA) expected to start commissioning from H2 FY26.
→Total capex plan of approx. INR 14,000 crore till 2027; around INR 7,000 crore committed, balance for Phase 2 expansions.
→Investment in polycarbonate compounding via INR 34.5 crore in OXOC Chemical Limited for forward integration.
→New R&D center near Vadodara with approx. INR 115 crore capex (66% utilized), supporting specialty chemicals and polycarbonate compounding.
→Projects including MIBK/MIBC, acetophenone, nitric acid, cumene hydroperoxide, hydrogenation blocks under commissioning in next 6-12 months.
→Funding from a balanced mix of debt and equity; liquid surplus (~INR 800 crore) and available credit lines support investment plans.

How does Deepak Nitrite Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Deepak Nitrite Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Deepak Nitrite Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio